BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 2020;12:1053-66. [PMID: 32772617 DOI: 10.2217/imt-2020-0163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim W, Kim HJ. An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Rev Clin Immunol 2023;19:111-21. [PMID: 36414430 DOI: 10.1080/1744666X.2023.2151441] [Reference Citation Analysis]
2 Ghosh K, Ghosh K. Monoclonal antibodies used for the management of haematological disorders. Expert Rev Hematol 2022. [PMID: 35504000 DOI: 10.1080/17474086.2022.2073213] [Reference Citation Analysis]
3 Luitel P, Ghimire A, Upadhyay D, Ojha R. Efficacy of monoclonal antibodies in neuromyelitis optica: An updated systematic review with meta‐analysis. Clinical & Exp Neuroim 2022. [DOI: 10.1111/cen3.12695] [Reference Citation Analysis]
4 Ghosh K, Ghosh K. Monoclonal antibodies used for management of hematological disorders. JHAS 2021;1:12-21. [DOI: 10.25259/jhas_2_2021] [Reference Citation Analysis]
5 Waliszewska-Prosół M, Chojdak-Łukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects. Int J Mol Sci 2021;22:2801. [PMID: 33802046 DOI: 10.3390/ijms22062801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]